IPCI (MC $63 M ) 7 Drugs awaiting FDA approval /Low Float Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPCI (MC $63 M ) 7 Drugs awaiting FDA approval /Low Float

Public Reply Prvt Reply Mark as Last Read File

PreviousNext

From: BioHero	7/16/2014 10:46:21 AM
	of 1

Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00 Analyst Andre Uddin stated, "We expect the stock to appreciate as new generic products are launched, the company's revenue base builds and Rexista-oxycodone moves to pivotal development." The company is an emerging drug delivery company that researches, develops and manufactures brand as well as generic controlled-release oral solid dosage drugs. The company received approval of its first generic product, Focalin XR, in November 2013 and its marketing partner Par Pharmaceutics immediately launched the drug at the end of November 2013. The company has a total of seven controlled-release generic drugs that are awaiting FDA approval. They expect four new generic product approvals and launches in the next 12 to 18 months. Mackie Research believes investors should focus their intention on Rexista-oxycodone, as they expect the company to monetize this asset by licensing it out in 12 to 18 months. As a unique abuse-resistant opioid OxyContin formulation, potentially best in class for the treatment of pain, it is the most important product in the company's pipeline, targeting a US$2.3 billion market opportunity. Drs. Isa and Amini Odidi are committed to the company, as they own approximately 26% of the issued and outstanding shares. They are world-renowned drug delivery scientists who have published over 100 papers. Their expertise in drug delivery development directly helped Biovail's initial growth phase, as they were responsible for developing the company's eight key generic drugs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

PreviousNext